STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Orexo (STO:ORX) and Neopharm Ltd of Israel have signed an exclusive distribution agreement that grants Neopharm rights to market and sell Abstral, Orexo’s product for treatment of breakthrough cancer pain, in Israel. Orexo will supply Neopharm with Abstral product in Israel and receive significant margin on the sales of the product. The agreement also includes milestone payments; however the financial terms are not disclosed. Neopharm will also be responsible for managing the regulatory approval process in Israel.
